| TITLE |
DATE |
| Exelixis' Cabozantinib Shows Encouraging Clinical Activity in
Patients With Metastatic Breast Cancer |
7-Dec-2011 |
| Reminder: Exelixis Announces Webcast of Annual R&D Day on This Thursday, December 1 |
29-Nov-2011 |
| Exelixis Signs CRADA With National Cancer Institute to Expand
Development Plan of Cabozantinib |
28-Nov-2011 |
| Exelixis Announces November 29th Webcast of Presentation at the Piper Jaffray Health Care Conference |
22-Nov-2011 |
| Exelixis Announces Initiation of Phase 2 Investigator-Sponsored Trial
of Cabozantinib in Women with Hormone Receptor-Positive Metastatic
Breast Cancer and Bone Metastases |
21-Nov-2011 |
| Exelixis Announces Webcast of Annual R&D Day on December 1 |
17-Nov-2011 |
| Exelixis' Cabozantinib Phase 2 Data Demonstrate Reduction in Bone Pain and Narcotic Analgesic Use in Patients with Previously Treated mCRPC |
12-Nov-2011 |
| Preliminary Data Demonstrate that 40 mg Daily Dose of Cabozantinib Yields a High Rate of Bone Scan Response in mCRPC |
12-Nov-2011 |
| Exelixis Announces November 15th Webcast of
Presentation at the Lazard Capital Markets 8th
Annual Healthcare Conference |
10-Nov-2011 |
| Exelixis to Initiate Cabozantinib '306 Trial with Pain Endpoint in
mCRPC |
31-Oct-2011 |
| Exelixis Announces Third Quarter 2011 Financial Results |
27-Oct-2011 |
| Exelixis Appoints Executive Vice President and Chief Commercial Officer |
25-Oct-2011 |
| Exelixis' Cabozantinib Meets Primary Endpoint in Phase 3 Clincial Trial for Medullary Thyroid Cancer |
24-Oct-2011 |
| Exelixis Announces October 27th Webcast of Third Quarter 2011
Financial Results Conference Call |
20-Oct-2011 |
| Exelixis Announces September 27th Webcast of Presentation at the JMP Securities Healthcare Conference |
21-Sep-2011 |
| Exelixis Announces Webcasts of Upcoming Investor Conference
Presentations |
9-Sep-2011 |
| Exelixis Reaches Pre-Specified Number of Events for Final Data Analysis in EXAM Trial |
7-Sep-2011 |
| Exelixis Announces September 8th Webcast of
Presentation at the Stifel Nicolaus Healthcare Conference |
2-Sep-2011 |
| Exelixis Announces August 10th Webcast of Presentation at the Canaccord Genuity Growth Conference |
8-Aug-2011 |
| Exelixis Announces Second Quarter 2011 Financial Results |
4-Aug-2011 |
| Exelixis Announces August 4th Webcast of Second Quarter 2011
Financial Results Conference Call |
21-Jul-2011 |
| Exelixis Provides Update on Cabozantinib Development Activities |
6-Jul-2011 |
| Exelixis' Cabozantinib Phase 2 Data Demonstrate Encouraging Clinical Activity in Patients with Metastatic Castration-Resistant Prostate Cancer |
6-Jun-2011 |
| Exelixis' Cabozantinib Demonstrates Broad Clinical Activity in Multiple Tumor Types |
5-Jun-2011 |
| Exelixis' Cabozantinib Demonstrates Encouraging Clinical Activity in Patients with Metastatic Ovarian Cancer |
4-Jun-2011 |
| Exelixis Announces Webcasts of June Investor Conference Presentations |
1-Jun-2011 |
| Reminder: Exelixis Announces Data Presentations, Webcast of Investor/Analyst Briefing and Other Activities in Conjunction with the 2011 ASCO Annual Meeting |
31-May-2011 |
| Data From a Phase 1 Clinical Trial of Exelixis' Cabozantinib Published in the Journal of Clinical Oncology |
23-May-2011 |
| CORRECTING and REPLACINGExelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
20-May-2011 |
| Exelixis Launches Online Summit Featuring Expert Perspectives on Cancer Treatment Advances and ASCO Highlights |
18-May-2011 |
| UPDATED: Exelixis Announces Data Presentations, Webcast of Investor/Analyst Briefing and Other Activities in Conjunction with the 2011 ASCO Annual Meeting |
13-May-2011 |
| Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
9-May-2011 |
| Exelixis Announces May 10th Webcast of Presentation at the Bank of America Merrill Lynch Health Care Conference |
5-May-2011 |
| Exelixis Announces First Quarter 2011 Financial Results |
3-May-2011 |
| Exelixis Announces May 4th Webcast of Presentation at the Deutsche Bank Securities Health Care Conference |
27-Apr-2011 |
| Exelixis Announces May 3rd Webcast of Its First Quarter 2011 Financial Results Conference Call |
21-Apr-2011 |
| Exelixis Announces April 7th Webcast of Presentation at the Leerink Swann Cancer Roundtable Conference |
4-Apr-2011 |
| Exelixis Announces Exercise in Full of Option to Purchase Additional Shares and Closing of Public Offering of Common Stock |
15-Mar-2011 |
| Exelixis Announces Updated Start Time for March 15 Webcast of Presentation at the Barclays Capital 2011 Global Healthcare Conference |
11-Mar-2011 |
| Exelixis Announces Pricing of $165.0 Million Public Offering of Common Stock |
9-Mar-2011 |
| Exelixis Announces Proposed Public Offering of Common Stock |
7-Mar-2011 |
| Exelixis Announces Webcasts of Investor Events in March (Cowen Presentation Canceled) |
2-Mar-2011 |
| Exelixis Reports Inducement Grants UnderNASDAQ Listing Rule 5635(c)(4) |
25-Feb-2011 |
| Exelixis Announces March 1 Webcast of Presentation at the Citi 2011 Global Health Care Conference |
24-Feb-2011 |
| Exelixis Announces Fourth Quarter and Full Year 2010 Financial Results |
22-Feb-2011 |
| Cabozantinib (XL184) Phase 2 Data Demonstrate Encouraging Clinical Activity in Patients with Castration-Resistant Prostate Cancer |
17-Feb-2011 |
| Reminder: Exelixis to Hold February 17th Investor Briefing Webcast at the ASCO 2011 Genitourinary Cancers Symposium |
15-Feb-2011 |
| Exelixis Announces February 22 Webcast of Its Fourth Quarter & Full Year 2010 Financial Results Conference Call |
10-Feb-2011 |
| Exelixis Announces February 17th Webcast of Investor Briefing at the ASCO 2011 Genitourinary Cancers Symposium |
8-Feb-2011 |
| Exelixis Announces February 14 Webcast of Presentation at the BIO CEO & Investor Conference |
7-Feb-2011 |
| Exelixis' XL184 Granted Orphan Drug Designation and Assigned the Generic Name Cabozantinib |
10-Jan-2011 |
| Exelixis Announces January 12 Webcast of Presentation at the J.P. Morgan 29th Annual Healthcare Conference |
17-Dec-2010 |
| Update:Exelixis Announces Webcast of Annual R&D Day on December 2 |
1-Dec-2010 |
| Exelixis Announces Webcast of Annual R&D Day on December 2 |
23-Nov-2010 |
| Exelixis Reports Promising Interim Data from Patients with Castration-Resistant Prostate Cancer Treated with XL184 |
18-Nov-2010 |
| Exelixis Reports Promising Interim Data From Patients With Ovarian Cancer Treated With XL184 |
18-Nov-2010 |
| Reminder: Upcoming Exelixis Investor Events |
17-Nov-2010 |
| Update on Upcoming Exelixis Investor Events |
15-Nov-2010 |
| Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
12-Nov-2010 |
| Exelixis Announces Webcasts of Investor Events in November and December |
10-Nov-2010 |
| Exelixis Announces Third Quarter 2010 Financial Results |
4-Nov-2010 |
| Exelixis Announces November 4 Webcast of Third Quarter 2010 Financial Results Conference Call |
26-Oct-2010 |
| Exelixis Announces Webcast of Presentation at the NewsMakers in the
Biotechnology Industry Conference |
15-Oct-2010 |
| Exelixis Licenses Programs to Bristol-Myers Squibb Company |
11-Oct-2010 |
| Exelixis Announces Webcasts of Presentations at Upcoming Investor
Conferences |
9-Sep-2010 |
| Exelixis Reports Inducement Grants Under Nasdaq Listing Rule
5635(C)(4) |
3-Sep-2010 |
| Exelixis Announces August 12 Webcast of Presentation at the Canaccord
Genuity 30th Annual Growth Conference |
6-Aug-2010 |
| Exelixis Announces Second Quarter 2010 Financial Results |
5-Aug-2010 |
| Exelixis Announces August 5 Webcast of Second Quarter 2010 Financial
Results Conference Call |
29-Jul-2010 |
| Exelixis Announces Appointment of New CEO |
30-Jun-2010 |
| Reminder:Exelixis Announces June 21 Webcast of Conference
Call Update on Development Collaboration with Bristol-Myers Squibb
Company for XL184 |
21-Jun-2010 |
| Exelixis Regains Full Rights to Develop and Commercialize XL184 |
21-Jun-2010 |
| Exelixis Announces June 21 Webcast of Conference Call Update on
Development Collaboration with Bristol-Myers Squibb Company for XL184 |
18-Jun-2010 |
| Exelixis Announces June 15 Webcast of Presentation at the Goldman
Sachs31st Annual Global Healthcare
Conference |
10-Jun-2010 |
| Exelixis Reports Updated Data from Multiple Clinical Trials of the
PI3K Inhibitor XL147 (SAR245408) to be Presented at ASCO |
7-Jun-2010 |
| Exelixis Announces June 9 Webcast of Presentation at the Jefferies
2010 Global Life Sciences Conference |
7-Jun-2010 |
| Exelixis Reports Updated Data from Multiple Clinical Trials of the
Dual PI3K and mTOR Inhibitor XL765 (SAR245409) to be Presented at ASCO |
6-Jun-2010 |
| Exelixis to Raise $160 Million through Financing Transactions with
Silicon Valley Bank and Deerfield Management |
3-Jun-2010 |
| Exelixis Announces Webcasts of ASCO Investor Briefingson June
5 and June 7 |
3-Jun-2010 |
| Exelixis Reports Updated Phase 2 Data for XL184 in Patients With
Recurrent Glioblastoma to Be Presented at ASCO |
20-May-2010 |
| Exelixis Reports Encouraging Interim Data from an Ongoing Adaptive
Randomized Discontinuation Trial of XL184 in Patients With Solid Tumors
to be Presented at ASCO |
20-May-2010 |
| Exelixis Reports Encouraging Interim Data From an Ongoing Phase 1b/2
Study of XL184 With or Without Erlotinib in Patients With Non-Small Lung
Cancer to be Presented at ASCO |
20-May-2010 |
| Exelixis Reports Long-Term Phase 1 Results in a Cohort of Medullary
Thyroid Cancer Patients Treated With XL184 to be Presented at ASCO |
20-May-2010 |
| Exelixis Reports Inducement Grants Under Nasdaq Listing Rule
5635(c)(4) |
14-May-2010 |
| Exelixis Announces First Quarter 2010 Financial Results |
11-May-2010 |
| Exelixis Announces May 10 Webcast of Presentation at the Ninth Annual
JMP Securities Research Conference |
3-May-2010 |
| Exelixis Announces May 11 Webcast of First Quarter 2010 Financial
Results Conference Call |
28-Apr-2010 |
| Exelixis Announces May 5 Webcast of Presentation at the Deutsche Bank
35th Annual Health Care Conference |
15-Apr-2010 |
| 12 Abstracts Featuring Exelixis Compounds Accepted for Presentation
at 2010 ASCO Annual Meeting |
14-Apr-2010 |
| Exelixis Announces March 24 Webcast of Presentation at the Barclays
Capital Global Healthcare Conference |
16-Mar-2010 |
| Exelixis Announces Fourth Quarter and Full Year 2009 Financial Results |
9-Mar-2010 |
| Exelixis Announces Restructuring |
8-Mar-2010 |
| Exelixis Announces March 10 Webcast of Presentation at the Cowen and Company 30th Annual Healthcare Conference |
4-Mar-2010 |
| Exelixis Announces March 9 Webcast of Its Fourth Quarter and Full Year 2009 Financial Results Conference Call |
2-Mar-2010 |
| Exelixis Announces February 9 Webcast of Presentation at the 12th
Annual BioCEO and Investor Conference |
4-Feb-2010 |
| Exelixis Announces January 12 Webcast of Presentation at the 28th
Annual J.P. Morgan Healthcare Conference |
9-Dec-2009 |
| Exelixis Announces December 1 Webcast of Presentation at Piper Jaffray's 21st Annual Healthcare Conference |
25-Nov-2009 |
| Exelixis Announces Webcast of Its Fifth Annual R&D Day on December 2 |
24-Nov-2009 |
| Exelixis Reports Encouraging Phase 1 Data for the PI3K Inhibitor Xl147 (SAR245408) in Combination with Erlotinib at the AACR-NCI-EORTC Conference |
18-Nov-2009 |
| Exelixis Reports Encouraging Phase 1 Data for the PI3K Inhibitor XL147 (SAR245408) in Combination with Paclitaxel and Carboplatin at the AACR-NCI-EORTC Conference |
17-Nov-2009 |
| Exelixis Announces November 18 Webcast of Presentation at Lazard's 6th Annual Healthcare Conference |
13-Nov-2009 |
| Thirteen Abstracts Featuring Exelixis Compounds Accepted for Presentation at the 2009 AACR-NCI-EORTC International Conference |
4-Nov-2009 |
| Exelixis Announces Third Quarter 2009 Financial Results |
29-Oct-2009 |
| Exelixis and Bristol-Myers Squibb Report New Phase 2 Data for XL184 in Patients With the Most Common and Aggressive Form of Brain Cancer |
23-Oct-2009 |
| Exelixis Announces October 29 Webcast of Third Quarter 2009 Financial Results Conference Call |
14-Oct-2009 |
| Exelixis Announces Webcasts of Three Presentations at Healthcare and Biotechnology Conferences in September 2009 |
4-Sep-2009 |
| Exelixis Announces August 11 Webcast of Presentation at the Canaccord Adams 29th Annual Global Growth Conference |
7-Aug-2009 |
| Exelixis Announces Second Quarter 2009 Financial Results |
30-Jul-2009 |
| Exelixis Announces July 30 Webcast of Its Second Quarter 2009 Financial Results Conference Call |
16-Jul-2009 |
| Exelixis Announces June 24 Webcast of Presentation at the Piper Jaffray Europe Conference |
16-Jun-2009 |
| Exelixis Announces June 9 Webcast of Presentation at the Goldman Sachs Thirtieth Annual Healthcare Conference |
4-Jun-2009 |
| Exelixis Reports Encouraging Phase 1 Data To Be Presented at ASCO for XL765, a Dual Inhibitor of PI3K and mTOR |
1-Jun-2009 |
| Exelixis Reports Encouraging Phase 1 Data To Be Presented at ASCO for XL147, a Selective Inhibitor of PI3K |
1-Jun-2009 |
| Exelixis and BMS Report Phase 2 Data to Be Presented at ASCO for XL184 in Patients with Previously Treated Glioblastoma Multiforme |
31-May-2009 |
| Exelixis Reports Encouraging Phase 1 Data to Be Presented at ASCO for XL228, a Multi-Targeted Inhibitor of Key Cancer Signaling Kinases |
30-May-2009 |
| Exelixis and Sanofi-aventis Sign Global License Agreement for XL147 & XL765 and Launch Broad Collaboration for Discovery of PI3K Inhibitors |
28-May-2009 |
| Exelixis Announces May 28 Webcast to Discuss New Collaboration Focused on PI3K Program |
28-May-2009 |
| Exelixis Announces May 20 Webcast of Presentation at the JMP Securities Eighth Annual Research Conference |
18-May-2009 |
| Exelixis Announces June 1 Webcast of Its ASCO Investor and Analyst Briefing |
15-May-2009 |
| Exelixis Announces First Quarter 2009 Financial Results |
7-May-2009 |
| Exelixis and Boehringer Ingelheim Enter into Collaboration for Development of S1P1 Receptor Agonists in the Field of Autoimmune Diseases |
7-May-2009 |
| Exelixis Announces May 12 Webcast of Presentation at the Bank of America & Merrill Lynch 2009 Health Care Conference |
6-May-2009 |
| Exelixis Announces May 7 Webcast of Its First Quarter 2009 Financial Results Conference Call |
27-Apr-2009 |
| Seven Abstracts Featuring Exelixis Compounds to Be Presented at 2009 ASCO Annual Meeting |
21-Apr-2009 |
| Exelixis Announces March 17 Webcast of Presentation at the Cowen and Company 29th Annual Health Care Conference |
13-Mar-2009 |
| Exelixis Announces March 10 Webcast of Presentation at the Barclays Capital Global Healthcare Conference |
5-Mar-2009 |
| Exelixis Announces Fourth Quarter and Full Year 2008 Financial Results |
4-Mar-2009 |
| Exelixis Announces March 4 Webcast of Its Fourth Quarter and Full Year 2008 Financial Results Conference Call |
25-Feb-2009 |
| Exelixis Announces February 10 Webcast of Presentation at the 11th Annual BIO CEO & Investor Conference |
5-Feb-2009 |
| Exelixis Announces January 13 Webcast of Presentation at the 27th Annual JPMorgan Healthcare Conference |
18-Dec-2008 |
| Bristol-Myers Squibb and Exelixis Enter Global Collaboration on Two Novel Cancer Programs |
12-Dec-2008 |
| Reminder: Exelixis Announces December 12 Webcast of Its Fourth AnnualR&D Day |
8-Dec-2008 |
| Exelixis Reports Positive Phase 1 Data for XL228 at ASH Annual Meeting |
8-Dec-2008 |
| Exelixis Reports Phase 1 Data for XL019 at ASH Annual Meeting |
7-Dec-2008 |
| Exelixis Announces December 12 Webcast of Its Fourth Annual R&D Day |
24-Nov-2008 |
| Exelixis and Bristol-Myers Squibb to Co-Develop XL413, a Selective Cdc7 Inhibitor |
24-Nov-2008 |
| Exelixis Announces December 2 Webcast of Presentation at the Piper Jaffray 20th Annual Health Care Conference |
21-Nov-2008 |
| Exelixis Announces November 18 Webcast of Presentation at the Lazard Capital Markets 5th Annual Healthcare Conference |
12-Nov-2008 |
| Exelixis Research Collaboration With Bristol-Myers Squibb Extended |
6-Nov-2008 |
| Exelixis Announces October 30 Webcast of Presentation at the 7th Annual BIO Investor Forum |
28-Oct-2008 |
| Exelixis Announces Third Quarter 2008 Financial Results |
27-Oct-2008 |
| Exelixis Reports Encouraging Phase 1 Data for XL184 at EORTC-NCI-AACR Symposium |
23-Oct-2008 |
| Exelixis Retains Rights to Develop and Commercialize XL184 |
23-Oct-2008 |
| Exelixis Reports Positive Phase 1 Data for XL228 at EORTC-NCI-AACR Symposium |
23-Oct-2008 |
| Exelixis Reports Positive Phase 1 Data for XL281 at EORTC-NCI-AACR Symposium |
23-Oct-2008 |
| Exelixis Reports Positive Phase 1 Data for PI3K/mTOR Inhibitor XL765 at EORTC-NCI-AACR Symposium |
22-Oct-2008 |
| Exelixis Reports Positive Phase 1 Data for PI3K Inhibitor XL147 at EORTC-NCI-AACR Symposium |
22-Oct-2008 |
| Exelixis Announces October 27 Webcast of Its Third Quarter 2008 Financial Results and Business Update Conference Call |
17-Oct-2008 |
| Exelixis Will Have 15 Presentations at the 2008 EORTC-NCI-AACR Annual Meeting |
16-Oct-2008 |
| Exelixis Submits Diligence Report for Cdc7 Inhibitor to Bristol-Myers Squibb |
15-Oct-2008 |
| Exelixis Files IND Application for XL888 |
2-Oct-2008 |
| Exelixis Announces October 6 Webcast of Presentation at the JMP Securities 3rd Annual Healthcare Focus Conference |
1-Oct-2008 |
| CORRECTING and REPLACING Exelixis Announces September 4 Webcast of Presentation at BioCentury's NewsMakers in the Biotech Industry Conference |
28-Aug-2008 |
| Exelixis Announces September 4 Webcast of Presentation at BioCentury's NewsMakers in the Biotech Industry Conference |
28-Aug-2008 |
| Exelixis Announces September 3 Webcast of Presentation at the Thomas Weisel Partners 2008 Healthcare Conference |
25-Aug-2008 |
| Exelixis Announces Second Quarter 2008 Financial Results |
5-Aug-2008 |
| Exelixis Announces August 8 Webcast of Presentation at the Bank of America 2008 Specialty Pharmaceuticals Conference |
31-Jul-2008 |
| Exelixis Notifies GlaxoSmithKline of Proof-of-Concept for XL184 |
28-Jul-2008 |
| Exelixis Announces August 5 Webcast of Its Second Quarter 2008 Financial Results and Business Update Conference Call |
22-Jul-2008 |
| Exelixis Initiates Phase 3 Trial of XL184 in Medullary Thyroid Cancer |
21-Jul-2008 |
| Exelixis Appoints Frances K. Heller As Executive Vice President of Business Development |
17-Jul-2008 |
| Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration |
27-Jun-2008 |
| Exelixis Announces June 25 Webcast of Presentation at the Piper Jaffray Europe Conference |
18-Jun-2008 |
| Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial |
16-Jun-2008 |
| Exelixis Presents Clinical Data Supporting the Safety and Initial Clinical Activity of XL228 in Chronic and Acute Leukemia |
13-Jun-2008 |
| Exelixis Announces June 19 Webcast of Presentation at the William Blair 28th Annual Growth Stock Conference |
12-Jun-2008 |
| Exelixis Announces June 5 Webcast of Conference Call Regarding Its $150 Million Funding Commitment from Deerfield Management |
5-Jun-2008 |
| Exelixis Receives $150 Million Funding Commitment From Deerfield Management |
5-Jun-2008 |
| Exelixis Announces June 10 Webcast of Presentation at the Goldman Sachs 29th Annual Global Healthcare Conference |
3-Jun-2008 |
| Exelixis Reports Phase 1 and Phase 2 Data For XL647 at ASCO |
2-Jun-2008 |
| Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO |
1-Jun-2008 |
| Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO |
31-May-2008 |
| REMINDER: Exelixis Will Webcast Its June 2 Investor and Analyst Briefing at ASCO |
28-May-2008 |
| Exelixis Announces June 2 Webcast of Its ASCO Investor and Analyst Briefing |
21-May-2008 |
| Exelixis Announces May 13 Webcast of Presentation at the Bank of America Health Care Conference |
8-May-2008 |
| Exelixis Announces First Quarter 2008 Financial Results |
6-May-2008 |
| Exelixis Announces May 6 Webcast of Its First Quarter 2008 Financial Results and Business Update Conference Call |
28-Apr-2008 |
| Exelixis Announces April 30 Webcast of Presentation at the Morgan Stanley Global Healthcare Unplugged Conference |
24-Apr-2008 |
| Seven Abstracts Featuring Exelixis Compounds Accepted for Presentation at 2008 ASCO Annual Meeting |
31-Mar-2008 |
| Exelixis Announces March 19 Webcast of Presentation at the Lehman Brothers Annual Global Healthcare Conference |
14-Mar-2008 |
| Option to Develop Exelixis Compound Exercised By Genentech |
14-Mar-2008 |
| Exelixis Announces March 17 Webcast of Presentation at the Cowen and Company Annual Health Care Conference |
12-Mar-2008 |
| Exelixis Announces March 4 Webcast of Presentation at the Susquehanna SIGnificant Options in Healthcare Conference |
28-Feb-2008 |
| Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results |
14-Feb-2008 |
| Exelixis Announces February 14 Webcast of Its Fourth Quarter and Full Year 2007 Financial Results Conference Call |
8-Feb-2008 |
| Exelixis Announces February 12 Webcast of Presentation at the 10th Annual BIO CEO and Investor Conference |
6-Feb-2008 |
| Exelixis Announces January 31 Webcast of Presentation at the 2008 Wachovia Healthcare Conference |
24-Jan-2008 |
| Exelixis and Bristol-Myers Squibb to Co-Develop XL139, an Inhibitor of the Hedgehog Pathway |
22-Jan-2008 |
| GSK Does Not Option XL784 for Further Development |
18-Jan-2008 |
| Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer |
7-Jan-2008 |
| Exelixis Announces Senior Management Promotions |
4-Jan-2008 |
| Exelixis Announces January 10 Webcast of Presentation at the 26th Annual JPMorgan Healthcare Conference |
2-Jan-2008 |
| Exelixis Submits XL139 Diligence Report to Bristol-Myers Squibb |
20-Dec-2007 |
| GlaxoSmithKline, Via Its Center of Excellence for External Drug Discovery, Exercises Its Option to Further Develop and Commercialize Exelixis' Anti-Cancer C-MET Inhibitor XL880 |
14-Dec-2007 |
| Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2 |
10-Dec-2007 |
| Reminder: Exelixis Announces December 10 Webcast of Its Analyst and Investor Briefing in Conjunction with The American Society Of Hematology 48th Annual Meeting |
6-Dec-2007 |
| Exelixis Announces December 10 Webcast of Its Analyst and Investor Briefing in Conjunction With The American Society of Hematology 48th Annual Meeting |
3-Dec-2007 |
| Exelixis to Receive Milestone Payment From Bristol-Myers Squibb for Achievement of Liver X Receptor Agonist Development Milestone |
29-Nov-2007 |
| Reminder: Exelixis Announces December 5 Webcast of Its Third Annual R&D Day |
28-Nov-2007 |
| Exelixis Announces November 28 Webcast of Presentation at the Lazard Capital Markets Fourth Annual Healthcare Conference |
21-Nov-2007 |
| Exelixis Announces November 27 Webcast of Presentation at the 19th Annual Piper Jaffray Health Care Conference |
21-Nov-2007 |
| Exelixis Announces December 5 Webcast of Its Third Annual R&D Day |
20-Nov-2007 |
| Exelixis Sells 80% Stake in Artemis to Taconic |
20-Nov-2007 |
| Exelixis Announces Third Quarter 2007 Financial Results and Business Update |
5-Nov-2007 |
| Phase 2 Trial Results for Exelixis' XL784 Presented at the 2007 American Society of Nephrology Conference |
2-Nov-2007 |
| Exelixis Announces November 6 Webcast of Presentation at the CIBC World Markets 18th Annual Healthcare Conference |
30-Oct-2007 |
| Exelixis Announces November 5 Webcast of its 2007 Third Quarter Financial Results Conference Call |
25-Oct-2007 |
| Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference |
24-Oct-2007 |
| Interim Phase 2 Data for Exelixis' XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer |
24-Oct-2007 |
| Updated Phase 1 Data for Exelixis' XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity |
23-Oct-2007 |
| Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy |
16-Oct-2007 |
| New Data for XL880, XL647 and XL184 to Be Presented at AACR-NCI-EORTC |
8-Oct-2007 |
| Exelixis Announces October 10 Webcast of Presentation at the 2007 Bio InvestorForum Conference |
5-Oct-2007 |
| Exelixis Research Collaboration With Bristol-Myers Squibb Extended |
21-Sep-2007 |
| Exelixis Submits XL880 Diligence Report to GlaxoSmithKline |
14-Sep-2007 |
| Exelixis Announces September 18 Webcast of Presentation at the Bank of America 2007 Investment Conference |
13-Sep-2007 |
| Exelixis Announces Closing of Public Offering of Common Stock |
13-Sep-2007 |
| Exelixis Commences Public Offering of Common Stock |
10-Sep-2007 |
| Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer |
4-Sep-2007 |
| Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation |
4-Sep-2007 |
| Exelixis Announces September 5 Webcast of Its 2007 IASLC Investor and Analyst Briefing |
29-Aug-2007 |
| GlaxoSmithKline Accelerates Review of Exelixis' XL880 |
23-Aug-2007 |
| Exelixis Announces Second Quarter 2007 Financial Results and Business Update |
7-Aug-2007 |
| Exelixis Announces August 7 Webcast of Its 2007 Second Quarter Financial Results Conference Call |
30-Jul-2007 |
| Exelixis Retains Right to Develop and Commercialize XL647 |
26-Jul-2007 |
| Update: Exelixis Announces July 26 Webcast of its Conference Call on Developments Under the Collaboration with GlaxoSmithKline |
25-Jul-2007 |
| Exelixis Announces June 21 Webcast of Presentation at the Second Annual Piper Jaffray London Health Care Conference |
18-Jun-2007 |
| Exelixis Announces June 19 Webcast of Presentation at the NASDAQ 19th Investor Program |
15-Jun-2007 |
| Exelixis Announces June 14 Webcast of Presentation at the Sixth Annual Needham Biotechnology & Medical Technology Conference |
11-Jun-2007 |
| Exelixis Announces June 12 Webcast of Presentation at the Goldman Sachs Twenty-Eighth Annual Global Healthcare Conference |
11-Jun-2007 |
| Exelixis Reports Integrated Data From Phase II Clinical Trials of XL999 at ASCO |
3-Jun-2007 |
| Exelixis Reports Comprehensive XL880 Phase I Data At ASCO |
2-Jun-2007 |
| Exelixis Announces May 31 Webcast of Presentation at the Bank of America 2007 Health Care Conference |
30-May-2007 |
| Six Abstracts Featuring Exelixis Compounds Accepted At ASCO Conference |
30-May-2007 |
| Exelixis Initiates Phase II Trial of XL647 in NSCLC Patients Who Have Previously Benefited From EGFR Inhibitors or Have the T790M Mutant Form of EGFR |
30-May-2007 |
| Exelixis Appoints Industry Veterans to Key Clinical Research and Drug Safety Positions |
29-May-2007 |
| Exelixis Files IND Application for XL019, a Novel Anticancer Compound Targeting the JAK/STAT Signaling Pathway |
24-May-2007 |
| Exelixis Announces June 2 Webcast of Its ASCO Investor and Analyst Briefing |
15-May-2007 |
| Exelixis Announces First Quarter 2007 Financial Results and Business Update |
3-May-2007 |
| Exelixis Files IND Application for XL765 |
25-Apr-2007 |
| Exelixis Announces May 3 Webcast of Its 2007 First Quarter Financial Results and Business Update Conference Call |
24-Apr-2007 |
| Exelixis Reinitiates Clinical Development of XL999 in Patients With Non-Small Cell Lung Cancer |
24-Apr-2007 |
| Exelixis Announces April 25 Webcast of Presentation at the 7th Annual Fortis Biotech Conference |
23-Apr-2007 |
| Exelixis Appoints Experienced Clinician and Scientist to Vice President of Translational Medicine |
12-Apr-2007 |
| Exelixis Announces April 12 Webcast of Presentation at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference |
5-Apr-2007 |
| Exelixis Files IND Application for XL147 |
16-Mar-2007 |
| Exelixis Announces March 19 Webcast of Presentation at the Lehman Brothers 10th Annual Global Healthcare Conference |
14-Mar-2007 |
| Exelixis Announces March 13 Webcast of Presentation at the Cowen & Company 27th Annual HealthCare Conference |
9-Mar-2007 |
| Exelixis Announces Fourth Quarter 2006 and Full Year 2006 Financial Results |
13-Feb-2007 |
| Exelixis Appoints Carl B. Feldbaum, President Emeritus of the Biotechnology Industry Organization, to Its Board of Directors |
9-Feb-2007 |
| Exelixis Announces February 13 Webcast of Its Fourth Quarter and Full Year 2006 Financial Results Conference Call |
2-Feb-2007 |
| Exelixis Files IND Application for XL418 |
30-Jan-2007 |
| Exelixis Appoints Jose Baselga, M.D., a Leading Expert in Oncology Drug Discovery and Development, to its Scientific Advisory Board |
29-Jan-2007 |
| Exelixis Announces January 31 Webcast of Presentation at the Wachovia 2007 Small and Mid Cap Healthcare Conference |
26-Jan-2007 |
| Exelixis Announces January 11 Webcast of Presentation at the 25th Annual JPMorgan HealthCare Conference |
8-Jan-2007 |
| Exelixis Announces Senior Management Promotions |
4-Jan-2007 |
| Exelixis Announces January 3 Webcast Discussion of Its Co-Development Agreement With Genentech for Small Molecule Oncology Compound |
3-Jan-2007 |
| Exelixis Signs Co-Development Agreement With Genentech for Small Molecule Oncology Compound |
3-Jan-2007 |
| Exelixis Initiates Phase II Trial of XL880 in Patients with Gastric Cancer |
22-Dec-2006 |
| Exelixis Files IND Application for XL518 |
20-Dec-2006 |
| Exelixis and Bristol-Myers Squibb Sign New Collaboration Agreement to Discover and Develop Novel Oncology Compounds |
18-Dec-2006 |
| Exelixis Announces December 18 Webcast Discussion of Its New Collaboration to Co-Develop Novel Oncology Compounds |
18-Dec-2006 |
| Exelixis Announces December 1 Webcast of Presentation at Piper Jaffray's 18th Annual Health Care Conference |
28-Nov-2006 |
| Exelixis Announces December 4 Webcast of Its Second Annual R&D Day |
22-Nov-2006 |
| Helsinn to Discontinue Becatecarin Trial Program |
16-Nov-2006 |
| Exelixis Presents Updated Phase I XL880 Data at EORTC Conference |
9-Nov-2006 |
| Exelixis Reports Additional Data From a Phase I Trial of XL647 in Patients With Advanced Solid Tumors |
9-Nov-2006 |
| Exelixis Presents Preliminary Phase I XL184 Data |
9-Nov-2006 |
| Phase I Data for Exelixis' Kit Inhibitor XL820 Presented at EORTC |
8-Nov-2006 |
| Exelixis Reports Additional Data From the Phase I Trial of XL999 in Patients With Advanced Solid Tumors |
8-Nov-2006 |
| Exelixis Announces November 9 Webcast of Clinical Investigator Discussions of XL999, XL880, XL820 and XL184 Data |
3-Nov-2006 |
| Exelixis Announces November 7 Webcast of Presentation at Cowen and Company's 7th Annual Global Healthcare Conference |
3-Nov-2006 |
| Exelixis Announces November 6 Webcast of Presentation at the CIBC World Markets 17th Annual Healthcare Conference |
3-Nov-2006 |
| Exelixis Announces Third Quarter 2006 Financial Results |
2-Nov-2006 |
| Exelixis Suspends Enrollment of New Patients in XL999 Phase II Clinical Trial Program |
2-Nov-2006 |
| Exelixis Announces November 2 Webcast of Its Third Quarter 2006 Financial Results Conference Call |
1-Nov-2006 |
| Exelixis Announces October 18 Webcast of Presentation at the BIO Investor Forum 2006 Conference |
13-Oct-2006 |
| Exelixis Files IND Application for XL281 |
13-Oct-2006 |
| Exelixis Announces Closing of Public Offering of Common Stock |
11-Oct-2006 |
| Exelixis Announces Exercise of Option to Purchase Additional Shares by Underwriters |
10-Oct-2006 |
| Exelixis Announces Pricing of Public Offering of Common Stock |
5-Oct-2006 |
| Exelixis Announces Proposed Public Offering of Common Stock |
27-Sep-2006 |
| Exelixis Announces September 12 Webcast of Presentation at the Bear Stearns 19th Annual Healthcare Conference |
6-Sep-2006 |
| Exelixis Files IND Application for XL228 |
31-Aug-2006 |
| Exelixis Announces August 11 Webcast of Presentation at the 2006 Bank of America Specialty Pharmaceuticals Conference |
10-Aug-2006 |
| Exelixis Announces Second Quarter 2006 Financial Results |
8-Aug-2006 |
| Exelixis Initiates Phase II Clinical Development Program for XL647 in Patients With Metastatic Non-Small Cell Lung Cancer |
1-Aug-2006 |
| Exelixis Announces August 8 Webcast of Its Second Quarter 2006 Financial Results Conference Call |
26-Jul-2006 |
| Exelixis Initiates Phase II Clinical Development Program for XL880 in Patients With Papillary Renal Cell Carcinoma |
28-Jun-2006 |
| Exelixis Appoints Experienced Biotechnology Executive as Chief Medical Officer |
26-Jun-2006 |
| Exelixis Announces June 22 Webcast of Presentation at the 2006 Piper Jaffray Health Care Conference |
21-Jun-2006 |
| Exelixis Announces June 20 Webcast of Presentation at the Wachovia Securities 16th Annual Nantucket Equity Conference |
19-Jun-2006 |
| Exelixis Announces June 14 Webcast of Presentation at the 2006 Goldman Sachs Healthcare Conference |
12-Jun-2006 |
| Exelixis Announces June 12 Webcast of Presentation at the Pacific Growth Equities Life Sciences Conference |
9-Jun-2006 |
| Encouraging Phase I Trial Results for XL647 in Patients with Advanced Solid Malignancies Presented at ASCO |
3-Jun-2006 |
| Exelixis' XL880, the First Orally-Available MET Inhibitor in Clinical Development, Continues to Show Promise in a Phase I Trial in Patients With Advanced Solid Tumors |
3-Jun-2006 |
| Exelixis Announces June 3 Webcast of Clinical Investigator Discussions of Phase I Trial Results of XL647, XL880 and XL999 |
25-May-2006 |
| Additional Data From Phase I Trials of Exelixis Compounds XL647, XL880 and XL999 to be Reported at ASCO |
25-May-2006 |
| Exelixis Announces May 18 Webcast of Presentation at the 2006 Bank of America Healthcare Conference |
11-May-2006 |
| Exelixis Announces First Quarter 2006 Financial Results |
9-May-2006 |
| Exelixis Announces May 9 Webcast of Its First Quarter 2006 Financial Results Conference Call |
25-Apr-2006 |
| Exelixis Announces April 5th Webcast of Presentation at the CIBC Annual Biotechnology & Specialty Pharmaceuticals Conference |
30-Mar-2006 |
| Exelixis Initiates Phase II Clinical Program for XL784 |
27-Mar-2006 |
| Exelixis Announces March 30th Webcast of Presentation at the 13th Annual Future Leaders in Biotech Industry Conference |
23-Mar-2006 |
| Exelixis and Sankyo Sign Collaboration Agreement to Develop Novel Therapies for Cardiovascular Disease |
20-Mar-2006 |
| Exelixis Announces March 8th Webcast of Presentation at the 9th Annual Global Lehman Brothers Healthcare Conference |
2-Mar-2006 |
| Exelixis Announces March 7 Webcast of Presentation at the 26th Annual SG Cowen Healthcare Conference |
28-Feb-2006 |
| Exelixis Announces Fourth Quarter and Full Year 2005 Financial Results |
21-Feb-2006 |
| Exelixis Announces February 21 Webcast of Its Fourth Quarter and Year-End 2005 Financial Results and 2006 Outlook Conference Call |
8-Feb-2006 |
| Exelixis Announces January 9 Webcast of Presentation at the 24th Annual JPMorgan Healthcare Conference |
3-Jan-2006 |
| Exelixis and Wyeth Sign License Agreement Related to Novel Treatments for Metabolic and Liver Diseases |
22-Dec-2005 |
| Exelixis Initiates Phase II Clinical Program for XL999 |
20-Dec-2005 |
| Exelixis and Bristol-Myers Squibb Sign New Collaboration Agreement to Develop Novel Cardiovascular Disease Treatments |
6-Dec-2005 |
| Data From Phase I Trial of Exelixis' XL999 Establishing MTD Presented at Cancer Conference |
17-Nov-2005 |
| Data From Phase I Trial of Exelixis' XL647 Presented at Cancer Conference |
15-Nov-2005 |
| Promising Data From Phase I Trial of Exelixis' XL880 Presented at Cancer Conference |
15-Nov-2005 |
| Exelixis Announces December 6 Webcast of Its First Annual R&D Day |
14-Nov-2005 |
| Exelixis Announces Third Quarter 2005 Financial Results |
3-Nov-2005 |
| Exelixis to Host Clinical Investigator Discussions of Preliminary Phase I Trial Results of XL647, XL880 and XL999 |
2-Nov-2005 |
| Exelixis Announces November 9 Webcast of Presentation at the SG Cowen & Co. 6th Annual Global Healthcare Conference |
28-Oct-2005 |
| Exelixis Announces November 7 Webcast of Presentation at the CIBC 16th Annual Healthcare Conference |
28-Oct-2005 |
| Exelixis Announces November 3 Webcast of Its Third Quarter 2005 Financial Results Conference Call |
20-Oct-2005 |
| Data From Exelixis Phase I Clinical Trials of Xl647, Xl999 and Xl880 to Be Presented at International Conference on Molecular Targets and Cancer Therapeutics |
11-Oct-2005 |
| Exelixis Starts Three New Phase I Clinical Trials for Novel Compounds XL844, XL184 and XL784 |
22-Sep-2005 |
| Exelixis Announces September 21 Webcast of Presentation at the Bank of America 35th Annual Investment Conference |
15-Sep-2005 |
| Exelixis Announces September 12 Webcast of Presentation at the Bear Stearns 18th Annual Healthcare Conference |
6-Sep-2005 |
| Exelixis Announces Offering of Common Stock |
17-Aug-2005 |
| Exelixis Announces Phase II Trial Programs for Most Advanced Internally Developed Compounds |
15-Aug-2005 |
| Exelixis Announces Second Quarter 2005 Financial Results |
8-Aug-2005 |
| Exelixis Announces August 8 Webcast of its Second Quarter 2005 Financial Results Conference Call |
25-Jul-2005 |
| Exelixis Appoints Ian D. Malcolm as Vice President of Strategic Marketing |
25-Jul-2005 |
| Exelixis Initiates Phase I Clinical Trial for Anticancer Compound XL820 |
25-Jul-2005 |
| Exelixis Files IND Application for Anticancer Compound XL184 |
14-Jun-2005 |
| Exelixis Announces June 13 Webcast Discussion of Its Clinical Development Financing Strategy |
13-Jun-2005 |
| Exelixis and Helsinn Sign Agreement for XL119 (becatecarin) |
13-Jun-2005 |
| Exelixis Announces Transaction to Fund Clinical Development for XL647, XL999 and XL784 |
13-Jun-2005 |
| Exelixis Announces June 14 Webcast of Presentation at the Goldman Sachs 26th Annual Global Healthcare Conference |
7-Jun-2005 |
| Exelixis and Genentech Collaborate on Novel Therapeutics for Cancer, Inflammation, and Tissue Growth and Repair |
3-Jun-2005 |
| Exelixis Announces May 19 Webcast of Presentation at Banc of America Securities 2005 Healthcare Conference |
11-May-2005 |
| Exelixis Announces First Quarter 2005 Financial Results |
9-May-2005 |
| Exelixis Achieves $35 Million in Milestones From GSK |
9-May-2005 |
| Webcast Alert: Exelixis Announces Its First Quarter 2005 Financial Results Conference Call Webcast |
6-May-2005 |
| Exelixis Files IND Application for Novel Anticancer Compound XL844 |
2-May-2005 |
| Exelixis Announces May 9 Webcast of Its First Quarter 2005 Financial Results Conference Call |
25-Apr-2005 |
| Exelixis Files IND Application for Novel Anticancer Compound XL820 |
25-Apr-2005 |
| Exelixis Amends Collaboration With GenOptera |
1-Apr-2005 |
| Exelixis Announces April 5 Webcast of Presentation at CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference |
29-Mar-2005 |
| Exelixis Announces March 31 Webcast of Presentation at Lehman Brothers Eighth Annual Global Healthcare Conference |
24-Mar-2005 |
| Exelixis Initiates Phase I Trial for Anticancer Compound XL880 |
17-Mar-2005 |
| Exelixis Announces March 15 Webcast of Presentation at SG Cowen & Co.'s 25th Annual Health Care Conference |
8-Mar-2005 |
| Exelixis Announces March 1 Webcast of Presentation at SunTrust Robinson Humphrey's Therapeutics Conference |
23-Feb-2005 |
| Exelixis Announces Fourth Quarter and Year-End 2004 Financial Results |
16-Feb-2005 |
| Webcast Alert: Exelixis Inc. Announces Its Fourth Quarter Year-End Earnings Conference Call Webcast |
15-Feb-2005 |
| Exelixis Announces February 16 Webcast of Fourth Quarter and Year-End 2004 Financial Results and 2005 Outlook Conference Call |
2-Feb-2005 |
| Exelixis Announces January 26 Webcast of Presentation at the 17th Annual Piper Jaffray Health Care Conference |
18-Jan-2005 |
| Exelixis Files Resale Registration Statement Registering Securities Sold in Connection With Its Acquisition of X-Ceptor Therapeutics, Inc. |
14-Jan-2005 |
| Exelixis Announces January 11 Webcast Discussion of the Amendment to the GlaxoSmithKline Collaboration |
10-Jan-2005 |
| Exelixis Amends Collaboration With GlaxoSmithKline |
10-Jan-2005 |
| Exelixis to Webcast Presentation at the 23rd Annual JPMorgan Healthcare Conference |
6-Jan-2005 |
| Exelixis Files IND Application for Novel Anticancer Compound XL880 |
16-Dec-2004 |
| Exelixis Appoints Dr. Alan M. Garber to Board of Directors |
14-Dec-2004 |
| Exelixis Announces Third Quarter 2004 Financial Results |
8-Nov-2004 |
| Exelixis Files Universal Shelf Registration Statement |
27-Oct-2004 |
| Exelixis Initiates Phase 1 Clinical Trial for XL999 |
25-Oct-2004 |
| Exelixis Completes Acquisition of X-Ceptor |
19-Oct-2004 |
| Exelixis Releases Pre-Clinical Data on Two Spectrum Selective Kinase Inhibitors in Development - XL647 and XL999 - at EORTC |
30-Sep-2004 |
| Exelixis to Webcast Presentation at BioNetwork 2004 |
28-Sep-2004 |
| Exelixis Agrees to Acquire X-Ceptor Therapeutics |
28-Sep-2004 |
| Exelixis to Webcast Presentation at the UBS Life Sciences Conference |
20-Sep-2004 |
| Exelixis to Webcast Presentation at the Bear Stearns 17th Annual Healthcare Conference |
7-Sep-2004 |
| Exelixis Appoints George Poste to Board of Directors |
9-Aug-2004 |
| Exelixis Announces Second Quarter 2004 Financial Results |
5-Aug-2004 |
| Exelixis Announces Second Quarter 2004 Financial Results and Outlook Conference Call and Webcast |
22-Jul-2004 |
| Exelixis Restructures to Focus Resources on Expanding Clinical Pipeline |
30-Jun-2004 |
| Exelixis Files IND Application for Anticancer Compound XL999 |
29-Jun-2004 |
| Exelixis Initiates Phase 3 Clinical Trial of XL119 in Bile Duct Cancer |
23-Jun-2004 |
| Exelixis to Webcast Presentation at the Pacific Growth Equities Life Sciences Growth Conference |
4-Jun-2004 |
| Exelixis Initiates Phase 1 Trial for Anticancer Compound Xl647 |
3-Jun-2004 |
| Exelixis to Webcast Presentation at the Goldman Sachs 25th Annual Healthcare Conference |
1-Jun-2004 |
| Exelixis to Webcast Presentation at the Friedman Billings Ramsey 8th Annual Growth Investor Conference |
26-May-2004 |
| Exelixis to Webcast Presentation at the SunTrust Robinson Humphrey Therapeutics Conference |
5-May-2004 |
| Exelixis Announces First Quarter 2004 Financial Results |
4-May-2004 |
| REMINDER: Exelixis Announces First Quarter 2004 Financial Results and Outlook Conference Call and Webcast |
4-May-2004 |
| Exelixis to Webcast Presentation at CIBC World Markets' Annual Biotechnology and Specialty Pharmaceuticals Conference |
21-Apr-2004 |
| Exelixis Announces First Quarter 2004 Financial Results and Outlook Conference Call and Webcast |
20-Apr-2004 |
| Exelixis Describes the Discovery of Novel Cancer Targets at AACR |
29-Mar-2004 |
| Exelixis to Webcast Presentation at Biocentury's Future Leaders in the Biotech Industry Conference |
25-Mar-2004 |
| Exelixis Granted Orphan Drug Designation for Anticancer Agent XL119 |
15-Mar-2004 |
| Exelixis to Webcast Presentation at the Third Annual JMP Securities Research Conference |
3-Mar-2004 |
| Exelixis to Webcast Presentation at SG Cowen's 24th Annual Health Care Conference |
2-Mar-2004 |
| Exelixis Appoints Financial Expert to Board of Directors |
1-Mar-2004 |
| Exelixis to Webcast Presentation at the Lehman Brothers Seventh Annual Global Healthcare Conference |
26-Feb-2004 |
| Exelixis Publishes World's Most Comprehensive Collection of Functional Gene Knockouts in a Multicellular Organism |
23-Feb-2004 |
| Exelixis to Webcast Presentations at the 6th Annual BIO CEO and Investor Conference |
19-Feb-2004 |
| Exelixis Files IND Application for Anticancer Agent XL647 |
19-Feb-2004 |
| Exelixis Announces Fourth Quarter and Year-End 2003 Financial Results |
17-Feb-2004 |
| Exelixis Announces Fourth Quarter and Year-End 2003 Financial Results and 2004 Outlook Conference Call and Webcast |
17-Feb-2004 |
| Exelixis Announces Year-End 2003 Financial Results and 2004 Outlook Conference Call and Webcast |
3-Feb-2004 |
| Webcast Alert: Exelixis, Inc. Announces Year End 2003 Financial Release Webcast |
3-Feb-2004 |
| Exelixis to Webcast Presentation at the 16th Annual PiperJaffray Healthcare Conference |
21-Jan-2004 |
| Exelixis Announces Date of 2004 Annual Meeting of Stockholders |
15-Jan-2004 |
| Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference |
13-Jan-2004 |
| Exelixis Appoints Chief Financial Officer |
12-Jan-2004 |
| Exelixis to Webcast Presentation at the 22nd Annual JPMorgan Healthcare Conference |
7-Jan-2004 |
| Exelixis and Bristol-Myers Squibb Company Extend Oncology Collaboration |
18-Dec-2003 |
| Exelixis Files IND Application for XL119 |
17-Dec-2003 |
| Exelixis to Webcast Presentation at the CIBC World Markets Annual Healthcare Conference |
6-Nov-2003 |
| Exelixis Announces Third Quarter 2003 Financial Results |
5-Nov-2003 |
| Exelixis Announces Third Quarter 2003 Financial Results and Outlook Conference Call Notice |
5-Nov-2003 |
| Exelixis Announces R&D Management Changes |
30-Oct-2003 |
| Exelixis Announces Third Quarter 2003 Financial Results and Outlook Conference Call Notice |
21-Oct-2003 |
| Exelixis CEO Executes Planned Stock Sale |
9-Oct-2003 |
| Exelixis Identifies Mechanism of Action, Target of Key Herbicidal Compound For Dow AgroSciences |
7-Oct-2003 |
| Exelixis to Webcast Presentation at the Annual UBS Warburg Global Life Sciences Conference |
18-Sep-2003 |
| Exelixis to Webcast Presentation at the ThinkEquity Partners Growth Conference |
16-Sep-2003 |
| Ex The presentation will be webcast and may be accessed in the Events page under Investor Information on the Exelixis website at http://www.exelixis.com/index.asp?secPage=events . |
16-Sep-2003 |
| Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL119 Phase 3 Trial |
15-Sep-2003 |
| Exelixis Announces Second Quarter 2003 Financial Results |
6-Aug-2003 |
| WEBCAST ALERT: Exelixis Announces Second Quarter 2003 Financial Results And Outlook Conference Call and Webcast |
6-Aug-2003 |
| Exelixis and Dow AgroSciences Extend Research Collaboration |
5-Aug-2003 |
| Exelixis Announces Changes to Board of Directors |
31-Jul-2003 |
| WEBCAST ALERT: Exelixis Announces Second Quarter 2003 Financial Results And Outlook Conference Call and Webcast |
23-Jul-2003 |
| Exelixis, Inc. Announces Underwriters' Exercise of Option To Purchase Additional Shares |
7-Jul-2003 |
| Exelixis, Inc. Announces Pricing of Common Stock in Public Offering |
20-Jun-2003 |
| Exelixis Initiates Phase 1 Safety Trial for XL784 |
18-Jun-2003 |
| Exelixis Announces Public Offering of Common Stock |
12-Jun-2003 |
| Exelixis Appoints Steven P. James to Head Commercial Operations |
10-Jun-2003 |
| Exelixis Announces Phase 2 Data on Rebeccamycin Analogue in Hepatobiliary Tumors Presented at ASCO |
2-Jun-2003 |
| Exelixis Announces First Quarter 2003 Financial Results |
7-May-2003 |
| Exelixis Announces Departure of Chief Financial Officer |
6-May-2003 |
| Exelixis Announces First Quarter 2003 Financial Results and Outlook Conference Call and Webcast |
23-Apr-2003 |
| Exelixis Files IND for First Proprietary Anticancer Compound |
31-Mar-2003 |
| Exelixis Provides Update on Cancer Antibody Research Collaboration With Protein Design Labs |
25-Feb-2003 |
| Exelixis Announces Fourth Quarter and Year-End 2002 Financial Results |
19-Feb-2003 |
| Webcast Alert: Exelixis Announces Year-End 2002 Financial Results and 2003 Outlook Conference Call and Webcast |
19-Feb-2003 |
| Webcast Alert: Exelixis Announces Year-End 2002 Financial Results and 2003 Outlook Conference Call and Webcast |
5-Feb-2003 |
| Exelixis Announces Presentation of Preliminary Phase 2 Data on Rebeccamycin Analogue in Hepatobiliary Tumors |
3-Feb-2003 |
| Agrinomics Identifies New Genetic Mechanisms That Control Plant Resistance To Fungal Infection |
30-Jan-2003 |
| Agrinomics and Renessen Establish Alliance to Enhance Seed Oil Content |
19-Dec-2002 |
| Exelixis Announces Third Quarter 2002 Financial Results and Restructuring Plan |
7-Nov-2002 |
| Exelixis and GlaxoSmithKline Form Broad Alliance To Discover and Develop Novel Therapeutics |
28-Oct-2002 |
| Exelixis Announces Broad Alliance with GlaxoSmithKline to Discover and Develop Novel Therapeutics |
28-Oct-2002 |
| Exelixis Announces Third Quarter 2002 Financial Results Conference Call and Webcast |
24-Oct-2002 |
| Exelixis Announces Second Quarter 2002 Financial Results |
6-Aug-2002 |
| Exelixis and Bristol-Myers Squibb Select Cancer Targets, Triggering Milestone |
6-Aug-2002 |
| Exelixis and Bristol-Myers Squibb Renew Mechanism of Action Collaboration |
5-Aug-2002 |
| Exelixis Delivers Assays to Bayer CropScience for Screening to Identify Novel Crop Protection Compounds |
31-Jul-2002 |
| Exelixis Announces Second Quarter 2002 Financial Results Conference Call and Webcast |
24-Jul-2002 |
| Exelixis Announces the Discovery of Two Proteins Involved in Alzheimer's Disease |
8-Jul-2002 |
| Exelixis Identifies Mechanism of Action, Target of Key Herbicidal Compound For Dow AgroSciences |
1-Jul-2002 |
| Exelixis Appoints Director of Preclinical Development |
11-Jun-2002 |
| Artemis Pharmaceuticals and Merck Collaborate To Develop Customized Mouse Models |
10-Jun-2002 |
| Exelixis Announces First Quarter 2002 Financial Results |
6-May-2002 |
| Exelixis and Merck Establish Chemistry Collaboration |
1-May-2002 |
| Exelixis Announces First Quarter 2002 Financial Results Conference Call and Webcast |
29-Apr-2002 |
| Exelixis and Collaborators Are First to Identify New Role for Immunity Gene |
17-Apr-2002 |
| Exelixis Delivers Novel Crop Protection Targets to Bayer Through Genoptera Joint Venture |
15-Apr-2002 |
| Exelixis Provides New Insights Into VEGF Signaling |
8-Apr-2002 |
| Bayer and Exelixis Joint Venture, Genoptera, is First to Sequence Heliothis Moth Genome |
3-Apr-2002 |
| Exelixis Delivers Multiple Cancer Antibody Targets to Protein Design Labs |
1-Apr-2002 |
| Exelixis Announces Fourth Quarter and Year End Financial Results |
20-Mar-2002 |
| Exelixis Announces Year End 2001 Financial Results Conference Call and Webcast |
13-Mar-2002 |
| Exelixis Adds Depth and Experience to Drug Development Organization With Key Appointments |
11-Mar-2002 |
| Exelixis Appoints Robert M. Myers As Executive Vice President, Pharmaceuticals |
4-Feb-2002 |
| Exelixis Identifies Additional Crop Protection Targets |
17-Jan-2002 |
| Agrinomics Delivering Arabidopsis Genome Ahead of Schedule |
16-Jan-2002 |
| Exelixis and Schering-Plough Collaborate on Customized Compound Library |
7-Jan-2002 |
| Exelixis and Cytokinetics Establish Chemistry Collaboration |
3-Jan-2002 |
| Exelixis Announces Closing of Genomica Exchange Offer |
2-Jan-2002 |
| Exelixis Announces New Vice President of Corporate Communications |
2-Jan-2002 |
| Exelixis and Genomica Announce Exchange Ratio |
26-Dec-2001 |
| Exelixis Adjusts Initial Genomica Exchange Offering Period Date to Account for Federal Holiday |
18-Dec-2001 |
| Bristol-Myers Squibb and Exelixis Select Initial Targets in Major Cancer Collaboration |
12-Dec-2001 |
| Dow AgroSciences and Exelixis Achieve Milestones in Discovery Collaboration |
29-Nov-2001 |
| Additional Cancer Targets Delivered by Exelixis to Protein Design Labs |
27-Nov-2001 |
| Exelixis, Inc. to Acquire Genomica Corporation |
19-Nov-2001 |
| Exelixis Announces Third Quarter Financial Results |
13-Nov-2001 |
| Exelixis Announces Third Quarter 2001 Financial Results Conference Call and Webcast |
6-Nov-2001 |
| Exelixis Collaboration in Immunity Yields Identification of New Gene Related to Inflammation |
11-Oct-2001 |
| Exelixis and Scios to Collaborate on High Throughput Drug Screening Library |
8-Oct-2001 |
| Exelixis Plant Sciences Receives National Science Foundation Award for Gene Discovery to Improve Rice |
24-Sep-2001 |
| Additional Milestones Reached by Exelixis in Joint Venture with Bayer |
29-Aug-2001 |
| Exelixis to Develop and Deliver New Compounds to Elan |
13-Aug-2001 |
| Exelixis Announces Second Quarter Financial Results |
8-Aug-2001 |
| Exelixis Delivers Drug Targets to Pharmacia Corporation |
7-Aug-2001 |
| Exelixis Announces Second Quarter 2001 Financial Results Conference Call And Webcast |
31-Jul-2001 |
| Exelixis Appoints Jeffrey R. Latts, M.D. Chief Medical Officer |
30-Jul-2001 |
| Exelixis Files Shelf Registration Statement |
27-Jul-2001 |
| Exelixis Establishes Proprietary Drug Discovery Program In Metabolism |
26-Jul-2001 |
| Exelixis / Bayer Joint Venture Genoptera Identifies New Genomics-Based Pesticide Targets |
24-Jul-2001 |
| Bristol-Myers Squibb and Exelixis Enter Pioneering Cancer-Fighting Alliance |
18-Jul-2001 |
| Exelixis Delivers Cancer Targets to Protein Design Labs |
11-Jul-2001 |
| Exelixis Announces First-Ever 'Functional Map' Linking Genes to Biological Activity in a Vertebrate |
6-Jun-2001 |
| Protein Design Labs and Exelixis Announce Oncology Antibody Drug Discovery Collaboration |
22-May-2001 |
| Exelixis Achieves Research Milestone in Bayer Joint Venture |
21-May-2001 |
| Exelixis Announces First Quarter 2001 Financial Results |
14-May-2001 |
| Exelixis Announces First Quarter 2001 Financial Results Conference Call on the Web |
7-May-2001 |
| AVI BioPharma and Exelixis Form Strategic Alliance on Functional Genomics and Antisense Drug Development |
27-Apr-2001 |
| Exelixis Acquires Artemis Pharmaceuticals GMBH |
23-Apr-2001 |
| Exelixis Delivers More Novel Targets to Bayer in Genoptera Joint Venture |
22-Mar-2001 |
| Exelixis Announces Fourth Quarter and Year End Financial Results |
28-Feb-2001 |
| Exelixis Announces Key Additions To Drug Discovery Team |
29-Jan-2001 |
| Orchid and Exelixis Collaborate to Develop Custom SNPcode™ Genotyping Kits |
10-Jan-2001 |
| Exelixis Completes Acquisition of Agritope |
8-Dec-2000 |
| Exelixis Announces Research Milestones in Bayer Joint Venture |
7-Dec-2000 |
| Exelixis Announces Key Additions to Executive Management Team |
27-Nov-2000 |
| Exelixis Delivers Several Targets To Bayer Through Genoptera Joint Venture |
15-Nov-2000 |
| Exelixis Announces Third Quarter Financial Results |
8-Nov-2000 |
| Agilent Technologies and Exelixis Sign Agreement for Customized DNA Microarrays |
12-Oct-2000 |
| Exelixis Delivers Two Assays for High Throughput Screening to Bayer in Genoptera Joint Venture |
9-Oct-2000 |
| Sangamo, Artemis Pharmaceuticals and Exelixis Initiate Collaboration to Create New Way of Generating Knock-Out Mice for Drug Discovery |
2-Oct-2000 |
| Exelixis To Acquire Key Plant Technology, Intellectual Property And Plant Biology Capabilities Through Acquisition of Agritope |
7-Sep-2000 |
| Exelixis and Bayer Reach Milestones |
10-Aug-2000 |
| Exelixis Announces Second Quarter Financial Results |
8-Aug-2000 |
| Dow AgroSciences and Exelixis Announce Crop Protection Collaboration |
11-Jul-2000 |
| Exelixis Licenses Forward Genetic Mouse Technology From Wisconsin Alumni Research Foundation |
6-Jul-2000 |
| Exelixis Announces Genomic Sequencing of Key Plant Disease Model System, Ustilago maydis |
22-Jun-2000 |
| Bristol-Myers Squibb and Exelixis Announce Expansion of Collaboration |
12-Jun-2000 |
| Exelixis Announces Cooperative Research and Development Agreement with the National Cancer Institute |
18-May-2000 |
| Exelixis Announces First Quarter Financial Results |
11-May-2000 |
| Exelixis Announces Exercise of Overallotment |
1-May-2000 |
| Exelixis Delivers Novel Drug Targets to Pharmacia Corporation |
23-Apr-2000 |
| Exelixis Raises $118 Million in Initial Public Offering of Common Stock |
10-Apr-2000 |
| Exelixis Identifies Conserved Function Of Tumor Suppressor Gene p53 |
31-Mar-2000 |
| Exelixis Announces Key Additions To Staff |
14-Mar-2000 |
| Exelixis Delivers Target For Screening To Pharmacia & Upjohn |
10-Feb-2000 |
| Exelixis Files Registration Statement for Initial Public Offering of Common Stock |
7-Feb-2000 |
| Bayer & Exelixis Establish Research Joint Venture |
11-Jan-2000 |
| Exelixis Announces New Additions To Senior Management Team |
7-Jan-2000 |
| Exelixis Pharmaceuticals And Pharmacia & Upjohn Expand Research Collaboration |
4-Nov-1999 |
| Bristol-Myers Squibb Company And Exelixis Pharmaceuticals Announce Unique Genetic Model Systems Alliance |
15-Sep-1999 |
| Sale of MetaXen Assets to Exelixis |
12-Jul-1999 |
| Exelixis Pharmaceuticals Delivers Target For Screening To Bayer AG |
1-Apr-1999 |
| Exelixis Pharmaceuticals And Pharmacia & Upjohn Form Research Collaboration |
2-Mar-1999 |
| Exelixis Pharmaceuticals and Bayer AG Sign Genetics Research Alliance |
22-May-1998 |
 |
